• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Mallinckrodt Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket

    6/5/23 8:10:18 AM ET
    $AFMD
    $AUMN
    $BANL
    $BJDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Precious Metals
    Basic Materials
    Get the next $AFMD alert in real time by email

    Gainers

    • Forza X1, Inc. (NASDAQ:FRZA) shares rose 85.6% to $2.32 in pre-market trading after the company tweeted Friday 'Get ready for something extraordinary! Stay tuned!'
    • Chijet Motor Company, Inc. (NASDAQ:CJET) shares surged 60.3% to $6.14 in pre-market trading after dipping around 33% on Friday.
    • Evaxion Biotech A/S (NASDAQ:EVAX) shares gained 41.8% to $2.17 in pre-market trading after the company announced that its melanoma trial met its primary endpoints. The company said proprietary AI technology pioneer was able to identify high-quality cancer vaccine targets.
    • Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) gained 33.8% to $18.19 in pre-market trading after the company announced overall response rate of 67% and clinical benefit rate of 93% in 69 heavily pretreated RANO-HGG evaluable patients in pediatric low-grade glioma trial.
    • Golden Minerals Company (NASDAQ:AUMN) shares rose 23.6% to $0.1373 in pre-market trading. Golden Minerals Company recently announced a 1-for-25 reverse stock split.
    • Dunxin Financial Holdings Limited (NYSE:DXF) gained 19.6% to $0.2463 in pre-market trading after gaining over 15% on Friday.
    • Kaspien Holdings Inc. (NASDAQ:KSPN) shares climbed 18.1% to $0.35 in pre-market trading. Kaspien recently announced a voluntary delisting from The Nasdaq Capital Market.
    • MultiMetaVerse Holdings Limited (NASDAQ:MMV) rose 17.2% to $2.39 in pre-market trading. MultiMetaVerse shares jumped 117% on Friday after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group.
    • Sentage Holdings Inc. (NASDAQ:SNTG) shares gained 17.2% to $2.80 in pre-market trading.
    • CBL International Limited (NASDAQ:BANL) rose 11.1% to $3.01 in pre-market trading. CBL International recently reported a 41.8% year-over-year revenue growth in FY22.

    Losers

    • Mallinckrodt plc (NYSE:MNK) fell 20.4% to $1.95 in pre-market. Mallinckrodt is considering options including filing for bankruptcy again, according to the Wall Street Journal.
    • Yunji Inc. (NASDAQ:YJ) shares dropped 15.5% to $0.2702 in pre-market trading. Yunji shares jumped over 50% on Friday after the company reported first-quarter financial results.
    • Minerva Surgical, Inc. (NASDAQ:UTRS) shares dropped 13.9% to $0.2522 in pre-market trading after surging over 46% on Friday.
    • Marker Therapeutics, Inc. (NASDAQ:MRKR) fell 13.1% to $1.60 in pre-market trading after gaining around 10% on Friday. Marker Therapeutics recently reported pre-clinical data of its MT-601 multiTAA-specific T cell product candidate MT-601 in lymphoma cells.
    • Cyxtera Technologies, Inc. (NASDAQ:CYXT) fell 12.5% to $0.1392 in pre-market trading after the company said, pursuant to the previously disclosed Restructuring Support Agreement it reached with certain of its lenders holding over two-thirds of its outstanding term loan, the Company and certain of its subsidiaries have initiated a pre-arranged court-supervised process under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of New Jersey.
    • Kaixin Auto Holdings (NASDAQ:KXIN) fell 11.1% to $0.3110 in pre-market trading after jumping over 16% on Friday.
    • UTime Limited (NASDAQ:UTME) fell 10.4% to $1.81 in pre-market trading after gaining 4% on Friday.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares fell 9.6% to $0.2205 in pre-market trading after gaining over 8% on Friday.
    • Affimed N.V. (NYSE:AFMD) fell 8.8% to $0.80in pre-market trading. Affimed reported the presentation at the ASCO Annual Meeting of safety and efficacy data from the EGFR mutant NSCLC expansion cohort of its ongoing phase 1/2 study investigating innate cell engager (ICE®) AFM24 as monotherapy.
    • SHL Telemedicine Ltd. (NASDAQ:SHLT) fell 8.6% to $11.61 in pre-market trading after gaining 10% on Friday.

     

    Now Read This: Market Volatility Falls Sharply Following Jobs Report; S&P 500 Records Weekly Gain

    Get the next $AFMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFMD
    $AUMN
    $BANL
    $BJDX

    CompanyDatePrice TargetRatingAnalyst
    Day One Biopharmaceuticals Inc.
    $DAWN
    3/10/2026$21.50Buy → Neutral
    H.C. Wainwright
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    Day One Biopharmaceuticals Inc.
    $DAWN
    1/13/2026$34.00Buy
    TD Cowen
    Day One Biopharmaceuticals Inc.
    $DAWN
    8/19/2025$25.00Overweight
    Piper Sandler
    Affimed N.V.
    $AFMD
    5/14/2025Buy → Neutral
    H.C. Wainwright
    Affimed N.V.
    $AFMD
    5/13/2025Outperform → Market Perform
    Leerink Partners
    Marker Therapeutics Inc.
    $MRKR
    3/5/2025$8.00Buy
    Canaccord Genuity
    Day One Biopharmaceuticals Inc.
    $DAWN
    10/9/2024$32.00 → $33.00Buy
    Needham
    More analyst ratings

    $AFMD
    $AUMN
    $BANL
    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 3 filed by new insider Mattsson Andreas Holm

    3/A - Evaxion A/S (0001828253) (Issuer)

    4/10/26 4:20:54 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 3 filed by new insider Soegaard Marianne

    3/A - Evaxion A/S (0001828253) (Issuer)

    4/2/26 4:06:38 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 3 filed by new insider Wegner Lars Aage Staal

    3/A - Evaxion A/S (0001828253) (Issuer)

    4/1/26 8:55:35 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AFMD
    $AUMN
    $BANL
    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Elms Steve bought $35,472 worth of shares (11,085 units at $3.20) (SEC Form 4)

    4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

    12/26/24 4:01:17 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner New Enterprise Associates 16, L.P. bought $1,773,600 worth of shares (554,250 units at $3.20) (SEC Form 4)

    4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

    12/23/24 4:40:48 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ross Neil bought $9,646 worth of shares (31,117 units at $0.31) (SEC Form 4)

    4 - Forza X1, Inc. (0001901305) (Issuer)

    9/30/24 4:34:00 PM ET
    $FRZA
    Marine Transportation
    Industrials

    $AFMD
    $AUMN
    $BANL
    $BJDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 30, 2024 - FDA Roundup: April 30, 2024

    For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/30/24 3:20:20 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2024 - FDA Roundup: April 26, 2024

    For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/26/24 3:10:22 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

    Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity

    4/24/24 12:52:43 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    $AUMN
    $BANL
    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01

    Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The trial has already yielded encouraging one- and two-year data including a 75% Objective Response Rate COPENHAGEN, Denmark, April 7, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has successfully completed the one-year extension of its phase 2 trial with personalized cancer vaccine EVX-01 with the last patient having now had last physician visit. Patients in the trial will continue to be monitored and data prepared for expected presentation in the second half of

    4/7/26 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

    ACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. ("Bluejay" or the "Company"), a medical diagnostics company focused on rapid, near-patient testing, today announced the successful enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the Company's Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings to determine patient acuity for sepsis triage and monitoring. The SYMON-II study has a target enrollment of 750 patients, and the Company expects to complete enrollment within the next 2 to 3 months, subject to site activity and patient flow. Importantly, the study's inclusion and exclusion criteria hav

    4/7/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress

    Using its pioneering AI-platform, AI-Immunology™, Evaxion has, in collaboration with the Gates Foundation, developed novel design concepts for polio vaccines potentially superior to those currently usedThe AI-Immunology™ concepts include hybrid capsid designs and de novo designed B-cell antigen approachesDespite polio vaccines being available for decades, the highly infectious viral disease continues to pose a global health riskEvaxion will also present data from its EVX-V1 vaccine program targeting cytomegalovirus at the World Vaccine Congress COPENHAGEN, Denmark, March 30, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pio

    3/30/26 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AFMD
    $AUMN
    $BANL
    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Day One Biopharmaceuticals downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Day One Biopharmaceuticals from Buy to Neutral and set a new price target of $21.50

    3/10/26 8:39:03 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen resumed coverage on Day One Biopharmaceuticals with a new price target

    TD Cowen resumed coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $34.00

    1/13/26 8:59:51 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    $AUMN
    $BANL
    $BJDX
    SEC Filings

    View All

    SEC Form 6-K filed by Kaixin Holdings

    6-K - Kaixin Holdings (0001713539) (Filer)

    4/10/26 4:13:02 PM ET
    $KXIN
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC TO-T/A filed by Day One Biopharmaceuticals Inc.

    SC TO-T/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    4/8/26 6:01:16 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 14D9/A filed by Day One Biopharmaceuticals Inc.

    SC 14D9/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    4/8/26 6:00:08 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    $AUMN
    $BANL
    $BJDX
    Leadership Updates

    Live Leadership Updates

    View All

    Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

    Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today a

    3/18/26 5:31:30 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CBL Appoints Mr. Yuan He to Board of Directors

    KUALA LUMPUR, Nov. 19, 2025 (GLOBE NEWSWIRE) -- CBL International Limited (NASDAQ:BANL) (the "Company" or "CBL"), the listing vehicle of the Banle Group ("Banle" or "the Group"), a leading marine fuel logistics company in the Asia-Pacific region, is pleased to announce the appointment of Mr. Yuan He to its board of directors, effective December 1, 2025. Mr. Yuan He has been serving as senior vice president of the Company and its predecessor entity since the inception of the Group in 2015. He is primarily responsible for the bunkering business division and the Group's management and strategic development. With over 17 years of experience in the oil and gas-related industries and business m

    11/19/25 7:30:00 AM ET
    $BANL
    Oil Refining/Marketing
    Energy

    Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

    HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory approvals, commercialization, and corporate strategy across multiple therapeutic modalities and in

    11/5/25 7:30:00 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    $AUMN
    $BANL
    $BJDX
    Financials

    Live finance-specific insights

    View All

    Yunji Announces Second Half and Fiscal Year 2025 Unaudited Financial Results

    HANGZHOU, China, March 27, 2026 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ:YJ), a leading membership-based social e-commerce platform, today announced its unaudited financial results for the second half and fiscal year ended December 31, 20251. Second Half 2025 HighlightsTotal revenues in the second half of 2025 were RMB158.7 million (US$22.7 million), compared with RMB183.8 million in the same period of 2024. The change was primarily due to the Company's continued strategy to refine its product selection across all categories and optimize its selection of suppliers and merchants, together with a deliberate scale-back of the marketplace business.Repeat purchase rate2 in th

    3/27/26 6:00:00 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    Yunji to Report Second Half and Fiscal Year 2025 Financial Results on March 27, 2026

    HANGZHOU, China, March 20, 2026 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ:YJ), a leading membership-based social e-commerce platform, today announced that it plans to release its unaudited financial results for the second half and fiscal year ended December 31, 2025, before the market opens on Friday, March 27, 2026. The earnings release will be available on the Company's investor relations website at https://investor.yunjiglobal.com/. The Company will hold a conference call on Friday, March 27, 2026 at 7:30 A.M. Eastern Time or 7:30 P.M. Beijing/Hong Kong Time to discuss its earnings. Listeners may access the call by dialing the following numbers:International:1-412-902-

    3/20/26 7:30:00 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    Evaxion plans to file 2025 annual report later today

    COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.   The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself.  As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 E

    3/5/26 8:02:13 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AFMD
    $AUMN
    $BANL
    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Golden Minerals Company

    SC 13G/A - Golden Minerals Co (0001011509) (Subject)

    11/14/24 7:11:10 PM ET
    $AUMN
    Precious Metals
    Basic Materials

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

    SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    11/14/24 4:30:11 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care